

SIRTeX

SIR-Spheres®
Y-90 resin microspheres

FLEXibility to Deliver Y-90 *Your Way*



Advancing to the next level.




The SIR-Spheres* Advantage

At Sirtex, we know that a multidisciplinary team approach is integral to the success of your practice and results in the best care for your patients.



*SIR-Spheres® Y-90 resin microspheres

The Activity You Want. The Coverage You Need.



One vial can offer up to 44M spheres with 7.3 GBq or as few as 2M spheres with 0.37 GBq.

All activity based on 8am EST delivery.

On average there are 44 million spheres in each SIR-Spheres Y-90 resin microspheres delivery vial with a standard deviation of 2.6 million. Engineering test results on file.

Take Control of Your Y-90 Program

SIR-Spheres Y-90 resin microspheres is the only SIRT that offers the following:

| Benefits | Advantages |
|---|--|
| FLEXdose Delivery Program | FLEXibility to administer the prescribed activity with more or less spheres |
| 3 dose options available 5 days per week | Enables optimization of patient scheduling and treatment planning |
| Next Day Dose (NDD) | May allow you to receive a dose as quickly as the next morning** |
| Order, Map and Treat same day or same week | Faster path from referral to treatment |
| Customized dose draw | Ability to modify treatment plan and/or time of treatment |

SIRT: selective internal radiation therapy

**All next day dose options are subject to availability

The Value of Using Resin Y-90



**3 Delivery Options
5 Days a Week**



Next Day Dose




Order — Map — Treat



Customized Dose Draw

FLEXdose Delivery Program 3 delivery options, 5 days a week

FLEXdose Delivery Program Animation



QR Reader Required

On average there are 44 million spheres in each SIR-Spheres Y-90 resin microspheres delivery vial with a standard deviation of 2.6 million. Engineering test results on file.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. **Indications for Use:** SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intrahepatic chemotherapy (IHAC) of FUDR (Floxuridine). **Warnings / Precautions:** Inadvertent delivery of the microspheres to locations other than the intended hepatic tumor may result in local radiation damage. Due to the radioactivity and the significant consequences of misplacing the microspheres in situ, this product must be implanted by physicians who have completed the Sirtex TEC training program. A SPECT scan of the upper abdomen immediately after implantation is recommended. Patients may experience abdominal pain immediately after administration and pain relief may be required. H-2 blocking agents may be administered the day before implantation and continued as needed to reduce gastric complications. **Side Effects:** Common side effects are fever, transient decrease of hemoglobin, mild to moderate abnormality of liver function tests, abdominal pain, nausea, vomiting, and diarrhea. Potential serious effects due to exposure to high radiation include acute pancreatitis, radiation pneumonitis, acute gastritis, radiation hepatitis, and acute cholecystitis. **Contraindications:** SIR-Spheres Y-90 resin microspheres should not be implanted in patients who have either had previous external beam radiation therapy to the liver; ascites or are in clinical liver failure. This device is contraindicated in patients with markedly abnormal synthetic and excretory liver function tests; greater than 20% lung shunting of the hepatic artery blood flow, or >30 Gy radiation absorbed dose to the lungs, as determined by the ^{99m}Tc MAA scan; disseminated extra-hepatic malignant disease, and portal vein thrombosis. This device should not be implanted in patients determined via angiogram to have an abnormal vascular anatomy that would result in significant reflux of the hepatic arterial blood flow to the stomach, pancreas, or bowel. **General Information:** SIR-Spheres Y-90 resin microspheres may only be distributed to a duly licensed or accredited facility capable of handling therapeutic medical isotopes. This product is radioactive and should thus be handled in accordance with all applicable standards and regulations. **Consult the Instructions for Use (www.sirtex.com) for a complete listing of indications, contraindications, side effects, warnings, and precautions.**



Manufacturer

Sirtex Medical Pty Ltd
Shop 6, 207 Pacific Highway
St Leonards, NSW 2065
Australia
Tel: +61 2 9964 8400
Fax: +61 2 9964 8410

Americas

Sirtex Medical Inc.
300 Unicorn Park Drive
Woburn, MA 01801
USA
Tel: +1 888 474 7839

www.sirtex.com



@SirtexMedical



@SIRspheresmicrospheres



company/sirtex-medical-limited



@SirtexMedicalUS

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.
©2021 Sirtex Medical Inc.

APM-US-002-06-21 V3

SIRTeX